Anticuerpos conjugados a fármaco: la nueva generación de terapias biotecnológicas contra el cáncer

Guadalupe Melgarejo-Rubio, Sonia M. Pérez-Tapia, Emilio Medina-Rivero, Marco A. Velasco-Velázquez

Research output: Contribution to journalArticlepeer-review

Abstract

Copyright: © 2020 Permanyer. Therapeutic antibodies are recombinant proteins used in the treatment of cancer. There is a new generation of monoclonal antibodies with activity against cancer cells, known as antibody-drug conjugates. These molecules are made up of three elements: a monoclonal antibody, a highly potent cytotoxic drug, and a chemical linker that binds them together. The antibody recognizes tumor antigens, thereby allowing targeted delivery of the cytotoxic agent to cancer cells. After recognizing its antigen, the antibody-drug conjugate is endocytosed by the target cells, where the protein fraction is degraded into lysosomes, releasing the cytotoxic drug. This article reviews antibody-drug conjugates general characteristics and describes the clinical evidence of efficacy and safety of the first four approved by regulatory agencies in the United States and Europe.
Original languageAmerican English
Pages (from-to)228-235
Number of pages8
JournalGaceta medica de Mexico
DOIs
StatePublished - 1 Jan 2020

Fingerprint

Dive into the research topics of 'Anticuerpos conjugados a fármaco: la nueva generación de terapias biotecnológicas contra el cáncer'. Together they form a unique fingerprint.

Cite this